mesoridazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 1712 | 5588-33-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A phenothiazine antipsychotic with effects similar to CHLORPROMAZINE.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
| 0.20 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 10.81 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 27, 1970 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N05AC03 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Phenothiazines with piperidine structure |
| FDA CS | M0016525 | Phenothiazines |
| MeSH PA | D014150 | Antipsychotic Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018492 | Dopamine Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
| MeSH PA | D014149 | Tranquilizing Agents |
| CHEBI has role | CHEBI:48561 | dopaminergic antagonists |
| CHEBI has role | CHEBI:65190 | typical antipsychotic drugs |
| FDA EPC | N0000175746 | Phenothiazine |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Schizophrenia | indication | 58214004 | DOID:5419 |
| Hyperkalemia | contraindication | 14140009 | |
| Neuroleptic malignant syndrome | contraindication | 15244003 | DOID:14464 |
| Orthostatic hypotension | contraindication | 28651003 | |
| Hypokalemia | contraindication | 43339004 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Stupor | contraindication | 89458003 | |
| Tardive dyskinesia | contraindication | 102449007 | |
| Prolonged QT interval | contraindication | 111975006 | |
| Coma | contraindication | 371632003 | |
| Granulocytopenic disorder | contraindication | 417672002 | |
| Congenital long QT syndrome | contraindication | 442917000 | |
| Predisposed to Torsades de Pointes Cardiac Arrhythmias | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.22 | Basic |
| pKa2 | 3.45 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 2A | GPCR | ANTAGONIST | Ki | 8.13 | PDSP | CHEMBL | |||
| D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 7.72 | PDSP | CHEMBL | |||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 8 | PDSP | |||||
| D(1A) dopamine receptor | GPCR | ANTAGONIST | Ki | 6.99 | IUPHAR | ||||
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 6.50 | CHEMBL | |||||
| 5-hydroxytryptamine receptor 1A | GPCR | ANTAGONIST | Ki | 6.98 | IUPHAR | ||||
| 5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.80 | PDSP | |||||
| 5-hydroxytryptamine receptor 6 | GPCR | Ki | 6.42 | PDSP | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 7.82 | PDSP | |||||
| Muscarinic acetylcholine receptor M3 | GPCR | Ki | 7.05 | PDSP | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 7.72 | PDSP | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | Ki | 7.22 | PDSP | |||||
| D(3) dopamine receptor | GPCR | Ki | 8.59 | PDSP | |||||
| D(4) dopamine receptor | GPCR | Ki | 8.04 | PDSP | |||||
| Histamine H1 receptor | GPCR | Ki | 8.74 | PDSP |
External reference:
| ID | Source |
|---|---|
| 4019816 | VUID |
| N0000147905 | NUI |
| D00795 | KEGG_DRUG |
| 32672-69-8 | SECONDARY_CAS_RN |
| 4019063 | VANDF |
| 4019816 | VANDF |
| C0025497 | UMLSCUI |
| CHEBI:6780 | CHEBI |
| CHEMBL1088 | ChEMBL_ID |
| CHEMBL1201052 | ChEMBL_ID |
| DB00933 | DRUGBANK_ID |
| D008653 | MESH_DESCRIPTOR_UI |
| C529599 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4078 | PUBCHEM_CID |
| 7227 | IUPHAR_LIGAND_ID |
| 2019 | INN_ID |
| 5XE4NWM740 | UNII |
| 203186 | RXNORM |
| 5058 | MMSL |
| d00889 | MMSL |
| 001490 | NDDF |
| 004594 | NDDF |
| 372852001 | SNOMEDCT_US |
| 75268009 | SNOMEDCT_US |
| 78684000 | SNOMEDCT_US |
Pharmaceutical products:
None